Successful CAR T cell therapy for the treatment of solid tumors requires exemplary expansion, persistence and fitness, ability to target tumor antigens safely. Here we address this constellation critical attributes successful cellular by using integrated technologies that simplify development derisk clinical translation. We have developed a CAR-CD19 secretes CD19-anti-Her2 bridging protein. Thi...